ION-260
- Generic Name
- ION-260
A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3
Phase 1
Terminated
- Conditions
- Spinocerebellar Ataxia Type 3
- Interventions
- Drug: BIIB132-Matching Placebo
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Biogen
- Target Recruit Count
- 8
- Registration Number
- NCT05160558
- Locations
- 🇺🇸
University of California - Los Angeles, Los Angeles, California, United States
🇺🇸University of Florida, Center for Movement Disorders, Gainesville, Florida, United States
🇵🇹Centro Hospitalar do Porto, Porto, Portugal
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath